financetom
Business
financetom
/
Business
/
Top Midday Gainers
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Top Midday Gainers
Mar 6, 2024 10:51 AM

01:33 PM EST, 03/06/2024 (MT Newswires) -- Aptorum Group ( APM ) shares soared after the company announced a reverse merger Wednesday with privately held YOOV Group, an AI-enabled software and automation platform.

"This transaction marks a significant milestone for YOOV," said Phil Wong, chief executive officer of YOOV Group, in a joint statement. YOOV shareholders will own more than a majority of shares of the combined company, expected to list on the Nasdaq.

Shares of Aptorum ( APM ) catapulted 565% as intraday trading volume soared to over 69.5 million from a daily average of about 6,400.

Rail Vision ( RVSN ) disclosed Wednesday the first commercial installation of its AI-driven Main Line Systems in a national railways line. The system uses sensors and AI algorithms to find and classify potential threats along railway tracks and provide early warnings to operators.

Shares advanced 73%, with intraday trading volume at over 80.3 million versus a daily average of about 5.7 million.

TRxADE HEALTH ( MEDS ) said Wednesday its board declared a special cash dividend of $8 per share.

The company said a portion of the proceeds from the sale of its web-based market platform assets will fund the distribution.

Shares rose 139% as intraday trading volume rose to more than 7.9 million compared with the stock's daily average of about 235,000.

Price: 11.46, Change: +9.79, Percent Change: +585.93

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Redhill Biopharma Awarded China Patent for Investigational Ebola Drug Opaganib
Redhill Biopharma Awarded China Patent for Investigational Ebola Drug Opaganib
May 6, 2024
07:43 AM EDT, 05/06/2024 (MT Newswires) -- Redhill Biopharma ( RDHL ) said Monday it was awarded a new patent in China for investigational drug opaganib as a therapy to inhibit single-stranded RNA virus replication, notably Ebola virus disease. The patent, issued by the Chinese National Intellectual Property Administration, is valid through 2035, according to Redhill. The company said opaganib...
KKR Goes Surgical: Snags Indian Medical Devices Company Healthium From Apax
KKR Goes Surgical: Snags Indian Medical Devices Company Healthium From Apax
May 6, 2024
KKR & Co. Inc. ( KKR )  announced the signing of definitive agreements to acquire Healthium Medtech Ltd. from an affiliate of Funds advised by Apax Partners LLP. Financial details were not disclosed. Based in India, Healthium is a medical devices company that develops, manufactures, and sells a broad range of surgical products worldwide. Akshay Tanna, Partner and Head of India Private Equity at KKR, said: “Under the...
Pfizer Names Andrew Baum as Chief Strategy, Innovation Officer
Pfizer Names Andrew Baum as Chief Strategy, Innovation Officer
May 6, 2024
07:42 AM EDT, 05/06/2024 (MT Newswires) -- Pfizer ( PFE ) said Monday it appointed Andrew Baum as chief strategy and innovation officer, effective June 3. The company said Baum joins the company from Citi where he was head of global healthcare and managing director of equity research. Baum succeeds Aamir Malik, who recently became Pfizer's ( PFE ) chief...
Xeris Biopharma Collaborating With Beta Bionics for Development, Commercialization of Glucagon Product
Xeris Biopharma Collaborating With Beta Bionics for Development, Commercialization of Glucagon Product
May 6, 2024
07:42 AM EDT, 05/06/2024 (MT Newswires) -- Xeris Biopharma Holdings ( XERS ) said Monday it has entered into an exclusive worldwide collaboration and license agreement with Beta Bionics for the development and commercialization of a glucagon product. Under the agreement, Beta Bionics will utilize Xeris' XeriSol technology on its bi-hormonal pump and pump systems for people with diabetes. Xeris...
Copyright 2023-2026 - www.financetom.com All Rights Reserved